adenosine diphosphate/stroke

INTRODUCTION The optimal antithrombotic therapy (combination of anticoagulants and antiplatelets drugs) for patients with non valvular atrial fibrillation (NVAF) after coronary stenting is unknown. In the last years, four randomized controlled trials compared double antithrombotic therapy with

ticagrelor is acyclo-pentyltriazolo-pyrimidine antiplatelet drug that inhibits the P2Y12which is a subtype of adenosine diphosphate (ADP)receptor. It is a potent , direct-acting oral agent and it is reversibly binding P2Y12 receptors antagonist unlike the irreversible agents as clopidogrel,

Acute coronary syndrome (ACS) is a disease with high mortality, morbidity and economic burden. Usually, it is caused by ischemic heart disease and atherosclerotic plaque rupture in the coronary arteries causing platelet activation, aggregation and thrombus formation. For decades, antiplatelet agents

Antiplatelet therapy is the cornerstone of medical treatment of patients experiencing an acute coronary syndrome (ACS). As a synergistic antiplatelet effect can be obtained by simultaneously inhibiting thromboxane-A2 and adenosine diphosphate P2Y12 platelet receptors, the current standard of care

Herbal medicine products are dietary supplements that people take to improve their health. Many herbs have been used for a long time for claimed health benefits. They are sold as tablets, capsules, powders, beverages, extracts and fresh or dried plants. Herbal medicines have been associated with

Carotid artery stenting (CAS) is an emerging treatment for atherosclerotic carotid stenosis. The main adverse event is embolic stroke during the procedure. Current medical management to prevent peri-procedural embolisation consists of dual antiplatelet therapy with clopidogrel and aspirin.

Antiplatelet therapy is the cornerstone in the management of patients with ACS. Aspirin interferes platelet aggregation activity by decreasing thromboxane synthesis through inhibition of cyclo-oxygenase (COX) enzymes. Low-dose (75-325mg/day) aspirin has been demonstrated to reduce the risk of

The PRINCE trial is a prospective, randomized, multi-centre, open-label, active-controlled, blinded-endpoint trial (a PROBE design concerning clinical trial). A total of approximately 952 patients (40years≤Age＜80years) with high-risk TIA (defined as an ABCD2 score ≥ 4 or the stenosis of offending

INTRODUCTION Glutamine (GLN) is the most abundant free amino acid in the body, and commonly known as a non-essential amino acid due to the ability of most cells to produce it. It has many essential metabolic functions in the organism; it is an energy substrate for most cells (especially for

Objective: The effect of antiplatelet therapy is impaired among patients, who recently underwent on-pump coronary artery bypass grafting. The impact of hybrid coronary revascularization using minimal invasive surgical techniques on the antiplatelet effect of aspirin and clopidogrel remains

The aim of this study is to evaluate the ability of a new POC device, the multiple electrode aggregometry (Multiplate, Dynabyte, Munich, Germany) to detect clopidogrel resistance and predict the clinical outcome in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) in

OPTImal Management of Antithrombotic agents: OPTIMA-2 trial Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the foundation antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is the most commonly used P2Y12 receptor

Percutaneous coronary intervention (PCI) targeting coronary lesions in patients with coronary syndromes leads to iatrogenic endothelial disruption and heightened platelet activation and aggregation. Blocking platelet aggregation with glycoprotein (GP) IIb/IIIa inhibitors has been demonstrated to be

This is a prospective, non-randomized, open-label, non-inferiority comparative effectiveness outcomes trial comparing clopidogrel EMs (confirmed by CYP2C19 genotype)and receiving clopidogrel at 75 mg/day with subjects receiving prasugrel at 5 and/or 10 mg/day. The antiplatelet drug clopidogrel is a